BUSINESS
Takeda to Launch New Manufacturing Facility for Leuplin; Aims to Maintain Its 110 Billion Yen Sales
Takeda Pharmaceutical plans to build a new manufacturing facility for its anticancer agent Leuplin (leuprorelin) at the location of its Osaka plant with costs of some 11 billion yen, it said on May 28. The construction is due to begin…
To read the full story
BUSINESS
- NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
October 28, 2025
- Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
October 28, 2025
- Novo to End Sales of Victoza in Japan, Fourth GLP-1 to Exit Market
October 28, 2025
- Eisai, Biogen Win Conditional Nod for Leqembi in Canada
October 28, 2025
- J&J Files for 4-Week SC Dosing of Rybrevant in Japan
October 28, 2025
In the dynamic pharmaceutical landscape, especially within the nuanced Japanese market, leadership hinges on acute awareness. This transcends surface-level observations, demanding a deep understanding of regulatory shifts, cultural sensitivities, and evolving patient needs. For leaders in this sector, particularly those…






